Shuttle Pharmaceuticals (US:SHPH) Newsfile·2025-11-21 14:30Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has successfully completed the acquisition of Molecule.ai, enhancing its technological capabilities in drug discovery and development [1][2][4]. Acquisition Details - The acquisition involved the purchase of substantially all assets and liabilities of Molecule.ai for a total price of $8 million, which includes an initial payment of $3 million and an additional contingent payment of $2 million based on performance milestones [2][3]. - The remaining purchase price will be a combination of cash and Shuttle common stock, to be determined by Molecule at its discretion and delivered over time [2]. Strategic Importance - This acquisition is seen as a strategic milestone for Shuttle Pharmaceuticals, aimed at advancing precision radiotherapy solutions and enhancing its drug discovery pipeline through Molecule.ai's AI platform [4]. - The integration of Molecule.ai's technology is expected to accelerate molecular innovation and improve efficiency in drug development processes [4]. Company Background - Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel drugs that enhance the efficacy of cancer therapy, particularly in sensitizing cancer cells to radiation [5].